Cabaletta Bio Inc. CEO Steven Nichtberger noted that his firm is "not the first to develop chimeric T cells as therapeutics, [but] we are the first to develop them in a way that leverages the potential of T cells to specifically eliminate only the B cells that cause autoimmune disease, thus sparing the healthy cells," and he told BioWorld that the lead indication – mucosal pemphigus vulgaris (PV) – represents a "hallmark for potential efficacy in a whole host of B-cell-mediated autoimmune diseases."